EUCTR2014-000870-20-DE进行中（未招募）1 期
An open-label, multicenter, controlled pharmaco-dynamic clinical trial to explore the Amyloid beta draining effect of Thiethylperazine (TEP) in subjects with early-to-mild dementia due to Alzheimer’s Disease in comparison to healthy volunteers - drainAD
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For AD subject only:
- •1.Newly diagnosed (= 12 months) early-to-mild Alzheimer’s disease as classified by a Mini-Mental State Examination (MMSE) Score of 25-18 reconfirmed at screening
- •2.AD diagnosis confirmed by recommended examinations in accordance with German DGN/DGPPN S3 Guideline Dementia” and to standard at the clinical unit by:
- •-psychometric and cognitive tests
- •-lumbar puncture in subjects with uncertain AD diagnosis following CNS imaging
- •-Clinical Dementia Rating (global CDR) is 0.5 or 1. Memory box score must be at least 0.5. Isolated or predominant episodic memory deficit, manifested as memory performance in the Logical Memory subscale (Delayed Paragraph Recall) from the Wechsler Memory Scale-III 1 SD below age adjusted norms, according to hospital standard)
- •3.AD subject has full legal competence according to investigator opinion
- •4.Ability to comply with requirements or cognitive and other testing for the entire length of the trial available
- •For healthy volunteer:
- •5.Subject is a non-demented volunteer, based on the assessment of medical history, physical examination and clinically laboratory data at screening as determined by the Investigator
- •For AD subject and healthy volunteer:
- •6.Age = 55 - = 75 years
- •7.Written informed consent to participate within this trial
- •8.Subject is on stable dose for at least 3 month prior to screening when receiving protocol-allowed concomitant medications at screening (e.g. acetylcholinesterase inhibitors, NMDA receptor antagonists)
- •9.For subject receiving anticholinergic agents, oral corticosteroids, propranolol, clonidine, antihistamines other than cetirizin and EBSTEL® a washout period of 4 weeks prior to screening must be completed. Concerning anticholinergic agents in Group 1a: only for high- to medium-potency anticholinergic agents a washout period of 4 weeks prior to screening must be completed.
- •10.Post-menopausal females (post menopausal amenorrhea for at least 2 years or surgically sterilized (hysterectomy), tubal ligation is not acceptable)
- •11.Male subjects with reproductive potential, and have not been surgically sterilized, that have been informed and agreed to that he and his partner must use a highly effective method of contraception (Pearl Index <1%) such as implants, injectables, combined oral contraceptives, or hormonal IUDs (intrauterine devices), or refrain from sexual intercourse during the trial and until 3 months after completion of the trial
- •12.Good general health with no additional disease states that could interfere with the trial due to the investigator’s assessment
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 70
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 70
排除标准
- •1.CSF cut-off values identified during routine Neurochemical Dementia Diagnostics
- •2.History or evidence of other significant neurological disease of the Central Nervous System (such as Parkinson's disease, multi-infarct dementia, fronto-temporal dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, pro-gressive supra nuclear palsy, epilepsy, myasthenia gravis, subdural hematoma or multiple sclerosis)
- •3.History of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities
- •4.Significant neuroimaging abnormalities, previously known or discovered on the MRI scan, including evidence of infection, infarction (> 3 mm in size), brain tumors (other than small meningiomas), or other focal lesions, multiple lacunas or lacunas in a critical memory structure or severe confluent microvascular disease (but not mild white matter changes, which are frequent with aging)
- •5.History or evidence of moderate congestive heart failure defined by the New York Heart Association criteria (class I-IV)
- •6.Clinical relevant ECG findings, abnormalities, e.g. pro-arrhythmic potential/effects on QT interval (QTc >450 msec for males, >470 msec for females, confirmed by manual assessment of ECG parameters)
- •7.History of new cardiovascular event within the last 6 months
- •8.Resting sitting vital signs: Systolic blood pressure = 100 mmHg or = 165 mmHg, Diastolic blood pressure = 60 mmHg or = 100 mmHg, heart rate = 50 beats/min or = 90 beats/min
- •9. Clinically significant renal disease or insufficiency, including but not limited to creatinine value of >1.5 mg/dl
- •10.ALT, AST, total bilirubin, or alkaline phosphatase >2.5 times the upper limit of normal laboratory range, or history of severe hepa-tobiliary disease (e.g. hepatitis B or C, or cirrhosis) without enzyme elevation
- •11.Positive tested for hepatitis B surface antigen (HBsAG) or hepatitis C virus/antibodies (anti-HCV) for the first time within the last 6 months prior to the Screening Visit
- •12.Positive tested for human immunodeficiency virus (HIV) at Screening Visit
- •13.Fasting triglycerides >2.5 times of the upper limit of normal
- •14.Uncontrolled diabetes (FBG > 150 mg/dl)
- •15.Coagulopathy or any kind of anti-coagulant therapy
- •16.Extrapyramidal syndrome
- •17.Elevation of prolactin, e.g. subject with prolactin-dependent breast cancer or pituitary tumor
- •18.History of severe psychiatric disease like psychotic disorder or current anxiolytic or neuroleptic therapy (for dementia-related or other psychiatric disorder) within the last 3 months of enrolment
- •19.Chronic depression or bipolar disorder or history of major depression within the past 2 years or history of any episode of treatment-resistant depression (requiring > 1 antidepressants, ECT etc.)
- •20.Significant history of alcohol abuse or drug abuse within the past 6 months (at the judgment of the investigator)
- •21.Current treatment with TEP or treatment up to 24 month prior to screening
- •22.Known incompatibility of TEP or phenothiazines
- •23.Subject is receiving the following treatment that may interact with TEP, e.g. adrenaline, tricyclic antidepressants, narcotics, bromocriptine, MAO inhibitors, CYP2D6 inhibitors, tramadol, pentetrazol, levodopa, anticonvulsants, medication causing extrapyramidal symptoms increases the likelihood of central nervous system side effects
- •24.Participation in a clinical trial involving another investigational drug within 4 weeks prior to screening visit
研究者
相似试验
招募中
4 期
A multicentre study of the dose concentration response of febuxostat in patients with chronic gout.ACTRN12616000959471St Vincent's Hospital120
招募中
Unknown
Efficacy and Safety of Dietary Fiber in Patients with Acute Ischemic StrokeAcute ischemic strokeAcute ischemic stroke, enteral nutrition, short-chain fatty acidsD000083242JPRN-jRCTs031230208Kurita Naohide38
进行中（未招募）
1 期
A study to evaluate the effect of Levonorgestrel-Emergency Contraception Tablet on Ovulation Inhibition in groups with a BMI that ranges underweight to obeseOvulationMedDRA version: 20.0Level: PTClassification code 10036251Term: Post coital contraceptionSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.0Level: LLTClassification code 10033313Term: Ovulation inhibitedSystem Organ Class: 100000004860EUCTR2019-001143-43-GBGedeon Richter Plc.520
进行中（未招募）
1 期
A pharmacokinetic (PK) and pharmacodynamic (PD) dose-ranging Phase II study of ticagrelor followed by a 4 weeks extension phase in paediatric patients with sickle cell diseaseInvestigation of platelet aggregation in paediatric patients with sickle cell diseaseMedDRA version: 18.1 Level: LLT Classification code 10040644 Term: Sickle cell disease System Organ Class: 100000004850EUCTR2014-001006-18-GBAstraZeneca AB73
进行中（未招募）
1 期
Multicenter, open-label, randomised, pharmacokinetic (PK) and pharmacodynamic (PD) dose-ranging Phase II study of ticagrelor followed by a double-blind, randomised, parallel-group, placebo-controlled 4 weeks extension phase in paediatric patients with sickle cell diseaseInvestigation of platelet aggregation in paediatric patients with sickle cell diseaseMedDRA version: 19.0Level: LLTClassification code 10040644Term: Sickle cell diseaseSystem Organ Class: 100000004850EUCTR2014-001006-18-ITAstraZeneca AB73